Year: 2021

Strong financial positionCash and cash equivalents of €247.9 million at the end of September 2021Reflects $107.6 million of gross proceeds raised in a US IPO and placement in Europe in the second quarter of 2021 Does not include $102.0 million of gross proceeds raised in a follow-on offering in the US and Europe in the fourth quarter of 2021Total revenue (excluding COVID) of €69.8 million in the first nine months of 2021 compared to €58.8 million in the first nine months of 2020Product sales of €45.5 million in the first nine months of 2021 (€45.9 million in the first nine months of 2020) €24.3 million of Other Revenues (revenues from collaborations, licensing and services) in the first nine months of 2021 (€12.9 million in the first nine months of 2020)Updated 2021 financial guidance (excluding COVID)Total revenues,...

Geneva, Switzerland, November 18, 2021 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery – Biology, Dr Robert Lütjens, will be attending the virtual German Equity Forum to be held November 22 – 24, 2021. Mr Dyer’s presentation is scheduled for November 23, 2021 at 08:00 EST / 14:00 CET. In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants. Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference...

  PRESS RELEASEParis, 18 November 2021, 7:00 CET2021 THIRD-QUARTER BUSINESS For the third quarter of 2021, the Parrot group achieved consolidated revenue of €14.5m and €11.6m on the basis of the current consolidation scope, i.e. excluding the revenues of the subsidiaries sold in January and October 2021, respectively MicaSense (sensors) and senseFly (fixed-wing drones). These disposals generated cash for Parrot of approximately €37m, including €25m received to date, and approximately €12m to be received by the end of 2023 and a decrease in cash consumption: the operating expenses of the divested subsidiaries totalled €6.2m for the 2020 financial year. On the basis of this new scope, the Parrot Group achieved a turnover of €31.2m over 9 months 2021, up by 10%. Parrot has thus completed its reorganisation in the commercial drone market...

Publication on November 18th, 2021, before market openingRegulated and privileged information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS Q3 2021 Business update Confirming strong results for 2021 EVS global leader in live video technology for broadcast and new media productions todayannounces its business update for the third quarter ending September 30th 2021. HIGHLIGHTSEVS announces that the 2021 full year revenue guidance is upgraded to land above EUR 135 million but still depending on potential supply chain issues. The 2021 booked revenue* on September 30th, 2021 amounts to 111.9Mio€ compared to 71.0Mio€ last year**. For 2022, EVS sees an increasing impact of the worldwide shortages in the supply chain of electronic components. EVS will distribute an interim dividend of EUR...

FRAMINGHAM, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the pricing of an underwritten public offering of 11,000,000 shares of its Class A common stock at a price to the public of $36.00 per share. The underwriters have a 30-day option to purchase up to an additional 1,650,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 22, 2021, subject to the satisfaction of customary closing conditions. Definitive Healthcare intends to use the net proceeds from the proposed offering (a) for acquisitions and general corporate purposes, including purchasing 7,000,000 newly issued limited liability...

VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) — Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) today announced that it has retained Renmark Financial Communications Inc. (“Renmark”) to provide investor relations services to the Company. Mayfair Gold President and CEO Patrick Evans commented: “Mayfair completed its IPO eight months ago and is rapidly gaining recognition for the size and quality of the Fenn-Gib project in the Timmins region of Ontario. We are pleased to have the support of Renmark to enhance Mayfair’s profile in the financial community.” Renmark’s mining industry clients include industry leaders such as Agnico Eagle, First Quantum, Wheaton Previous Metals and Lundin Gold. In consideration for the services, Renmark shall be paid up to C$8,000 per month, with effect from November...

NASHVILLE, Tenn., Nov. 17, 2021 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV), (“Clover Health”), a technology company committed to improving health equity for seniors, today announced the pricing of its previously announced underwritten public offering of 52,173,913 shares of its Class A Common Stock at a price of $5.75 per share. In addition, Clover Health has granted the underwriters a 30-day option to purchase up to 7,826,086 additional shares of its Class A Common Stock at the public offering price, less the underwriting discounts and commissions. The aggregate gross proceeds to Clover Health from the offering are expected to be approximately $300 million, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriters’ option to purchase additional...

GUANGZHOU, China, Nov. 17, 2021 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA, Darmstadt, Germany, in companion diagnostics (CDx) development for the MET inhibitor tepotinib in the mainland China market. The CDx test is based on Burning Rock’s self-developed next generation sequencing (NGS)-based liquid biopsy solution, OncoCompass Target™ panel. Tepotinib is an oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET (gene) alterations. Discovered and developed in-house at Merck KGaA, Darmstadt, Germany, tepotinib has a highly selective mechanism of action, with the potential to improve outcomes in aggressive tumors that have a poor prognosis and harbor these specific alterations. Tepotinib...